Currently, there are no guidelines that recommend the systematic evaluation of LKB1 mutational status in NSCLC, and current practice supports the use of ICI in first-line settings as well as in all advanced NSCLC patients without oncogenic driver mutations, regardless of LKB1 status. This evidence concerns the gene STK11 and non-small cell lung carcinoma.